Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125) - PubMed (original) (raw)
Comparative Study
. 2006 Oct;19(10):1386-94.
doi: 10.1038/modpathol.3800646. Epub 2006 Jul 28.
Affiliations
- PMID: 16880776
- DOI: 10.1038/modpathol.3800646
Free article
Comparative Study
Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125)
Subhash C Chauhan et al. Mod Pathol. 2006 Oct.
Free article
Abstract
Mucins are being implicated in diagnosis, prognosis, and as therapeutic targets due to their aberrant expression in a variety of carcinomas. Here, we have analyzed the expression of MUC4 and have compared its potential usefulness in early detection and prognosis of ovarian carcinoma alone and in combination with other mucin antigens, MUC1 and MUC16. Clinical significance of the differential mucin expression was evaluated by grouping the tumor samples in early (stage I and II) and advanced (stage III and IV) stage cases and histological subtypes (serous, mucinous, endometrioid and clear cell). Correlation of these mucins with patient's survival (n=63) was determined by Kaplan-Meier analysis in order to predict their prognostic value. MUC4 showed significant overexpression in tumor cases (P<0.0001) with highest incidence (92.0%) among all three mucins. A significant overexpression of MUC1 (P<0.018) and MUC16 (P<0.0001) was also observed in 83.0 and 79.0% of tumor samples, respectively. Notably, MUC4 expression was significantly higher (P</=0.004) compared to both MUC1 and MUC16 in early-stage ovarian tumor samples with 100% incidence. In advanced stage ovarian tumors, all the mucins displayed overall comparable expression, nonetheless, MUC4 had highest prevalence (88.0%) compared to MUC1 (84.0%) and MUC16 (81.0%). A combined panel of MUC4 with MUC16 detected 100% of the late-stage tumor cases without compromising the specificity. Among histological subtypes, only MUC4 displayed 100% (n=5) sensitivity in mucinous ovarian tumors, while MUC1 and MUC16 detected 40 and 20% cases, respectively. The expression of MUC4, however, did not significantly correlate with the survival of the ovarian cancer patient, while a significant correlation of MUC16 with poor prognosis was observed. In conclusion, our study demonstrates that MUC4 could be a potential candidate marker for early diagnosis of epithelial ovarian carcinoma and can be utilized in combination with MUC16 to achieve greater sensitivity for the detection of late-stage tumors.
Similar articles
- Expression of the transmembrane mucins, MUC1, MUC4 and MUC16, in normal endometrium and in endometriosis.
Dharmaraj N, Chapela PJ, Morgado M, Hawkins SM, Lessey BA, Young SL, Carson DD. Dharmaraj N, et al. Hum Reprod. 2014 Aug;29(8):1730-8. doi: 10.1093/humrep/deu146. Epub 2014 Jun 17. Hum Reprod. 2014. PMID: 24939955 Free PMC article. - Polymorphisms of MUC16 (CA125) and MUC1 (CA15.3) in relation to ovarian cancer risk and survival.
Williams KA, Terry KL, Tworoger SS, Vitonis AF, Titus LJ, Cramer DW. Williams KA, et al. PLoS One. 2014 Feb 13;9(2):e88334. doi: 10.1371/journal.pone.0088334. eCollection 2014. PLoS One. 2014. PMID: 24551091 Free PMC article. - Distinct evolution of the human carcinoma-associated transmembrane mucins, MUC1, MUC4 AND MUC16.
Duraisamy S, Ramasamy S, Kharbanda S, Kufe D. Duraisamy S, et al. Gene. 2006 May 24;373:28-34. doi: 10.1016/j.gene.2005.12.021. Epub 2006 Feb 24. Gene. 2006. PMID: 16500040 - Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG. McCluggage WG. Pathology. 2011 Aug;43(5):420-32. doi: 10.1097/PAT.0b013e328348a6e7. Pathology. 2011. PMID: 21716157 Review. - MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.
Felder M, Kapur A, Gonzalez-Bosquet J, Horibata S, Heintz J, Albrecht R, Fass L, Kaur J, Hu K, Shojaei H, Whelan RJ, Patankar MS. Felder M, et al. Mol Cancer. 2014 May 29;13:129. doi: 10.1186/1476-4598-13-129. Mol Cancer. 2014. PMID: 24886523 Free PMC article. Review.
Cited by
- Assessing the prognostic significance of MUC4β in mucoepidermoid carcinoma of the salivary glands: An immunohistochemical study.
Sawant PR, Spadigam A, Dhupar A, Syed S, Carvalho K. Sawant PR, et al. Heliyon. 2019 Nov 14;5(11):e02753. doi: 10.1016/j.heliyon.2019.e02753. eCollection 2019 Nov. Heliyon. 2019. PMID: 31844699 Free PMC article. - Monoclonal antibodies recognizing the non-tandem repeat regions of the human mucin MUC4 in pancreatic cancer.
Jain M, Venkatraman G, Moniaux N, Kaur S, Kumar S, Chakraborty S, Varshney GC, Batra SK. Jain M, et al. PLoS One. 2011;6(8):e23344. doi: 10.1371/journal.pone.0023344. Epub 2011 Aug 23. PLoS One. 2011. PMID: 21886786 Free PMC article. - The role of membrane mucin MUC4 in breast cancer metastasis.
Dreyer CA, VanderVorst K, Free S, Rowson-Hodel A, Carraway KL. Dreyer CA, et al. Endocr Relat Cancer. 2021 Nov 24;29(1):R17-R32. doi: 10.1530/ERC-21-0083. Endocr Relat Cancer. 2021. PMID: 34726614 Free PMC article. Review. - Ovarian cancer stem cells: Critical roles in anti-tumor immunity.
Ding J, Zhang Y, Che Y. Ding J, et al. Front Genet. 2022 Nov 10;13:998220. doi: 10.3389/fgene.2022.998220. eCollection 2022. Front Genet. 2022. PMID: 36437919 Free PMC article. Review. - Mucin (Muc) expression during pancreatic cancer progression in spontaneous mouse model: potential implications for diagnosis and therapy.
Rachagani S, Torres MP, Kumar S, Haridas D, Baine M, Macha MA, Kaur S, Ponnusamy MP, Dey P, Seshacharyulu P, Johansson SL, Jain M, Wagner KU, Batra SK. Rachagani S, et al. J Hematol Oncol. 2012 Oct 26;5:68. doi: 10.1186/1756-8722-5-68. J Hematol Oncol. 2012. PMID: 23102107 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous